Literature DB >> 30286483

The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

Mehri Jamilian1, Niloufar Kazemi Sabzevar1, Zatollah Asemi2.   

Abstract

Data on the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk of patients with polycystic ovary syndrome (PCOS) were collected. This investigation was conducted to evaluate the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk in women with PCOS. This randomized, double-blind, placebo-controlled trial was carried out on 60 women with PCOS, aged 18-40 years old. Participants were randomly divided into two groups to receive 250 mg/day magnesium plus 400 mg/day vitamin E supplements or placebo (n=30 each group) for 12 weeks. Fasting blood samples were taken at baseline and after the 12-week intervention to quantify related variables. After the 12-week intervention, compared with the placebo, magnesium and vitamin E co-supplementation led to a significant reduction in serum insulin levels (-1.1±3.0 vs. +1.6±3.7 μIU/ml, p=0.003) and homeostatic model of assessment for insulin resistance (-0.2±0.7 vs. +0.4±0.9, p=0.002), and a significant increase in the quantitative insulin sensitivity check index (+0.01±0.01 vs. -0.009±0.02, p=0.003). Furthermore, magnesium plus vitamin E supplementation significantly decreased serum triglycerides (-15.0±24.4 vs. +6.7±22.2 mg/dl, p=0.001) and VLDL-cholesterol concentrations (-3.0±4.9 vs. +0.6±2.4 mg/dl, P=0.01) compared with the placebo. A trend toward a greater decrease in total cholesterol levels was observed in magnesium plus vitamin E group compared to placebo group (-7.0±32.6 vs. +8.1±26.6 mg/dl, p=0.05). In conclusion, magnesium and vitamin E co-supplementation for 12 weeks to PCOS women had beneficial effects on parameters of insulin metabolism and few markers of cardio-metabolic risk. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30286483     DOI: 10.1055/a-0749-6431

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  9 in total

1.  Effects of antioxidant intervention in patients with polycystic ovarian syndrome: A systematic review and meta-analysis.

Authors:  Junde Zhao; Xiaohui Sui; Qingyu Shi; Dan Su; Zhiheng Lin
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 2.  Crosstalk of Magnesium and Serum Lipids in Dyslipidemia and Associated Disorders: A Systematic Review.

Authors:  Mihnea-Alexandru Găman; Elena-Codruța Dobrică; Matei-Alexandru Cozma; Ninel-Iacobus Antonie; Ana Maria Alexandra Stănescu; Amelia Maria Găman; Camelia Cristina Diaconu
Journal:  Nutrients       Date:  2021-04-22       Impact factor: 5.717

Review 3.  Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary Syndrome.

Authors:  Kristen P Hamilton; Rena Zelig; Anna R Parker; Amina Haggag
Journal:  Curr Dev Nutr       Date:  2019-10-03

4.  Effect of vitamin E supplementation on cardiometabolic risk factors, inflammatory and oxidative markers and hormonal functions in PCOS (polycystic ovary syndrome): a systematic review and meta-analysis.

Authors:  Moloud Payab; Mahbube Ebrahimpur; Ghazale Tefagh; Mostafa Qorbani; Farshad Sharifi; Yasaman Sharifi; Mahbubeh Sadat Ebrahimnegad Shirvani; Farzad Pourghazi; Rasha Atlasi; Zhaleh Shadman; Nafiseh Rezaei; Erfan Mohammadi-Vajari; Bagher Larijani
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

5.  Magnesium Status and Ca/Mg Ratios in a Series of Children and Adolescents with Chronic Diseases.

Authors:  Marlene Fabiola Escobedo-Monge; Enrique Barrado; Joaquín Parodi-Román; María Antonieta Escobedo-Monge; María Carmen Torres-Hinojal; José Manuel Marugán-Miguelsanz
Journal:  Nutrients       Date:  2022-07-18       Impact factor: 6.706

6.  The effect of magnesium alone or its combination with other supplements on the markers of inflammation, OS and metabolism in women with polycystic ovarian syndrome (PCOS): A systematic review.

Authors:  Ruiyun Li; Zhiyuan Li; Yi Huang; Kaiyan Hu; Bin Ma; Yuan Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

7.  Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Mohammad Alizadeh; Majid Karandish; Mohammad Asghari Jafarabadi; Lida Heidari; Roshan Nikbakht; Hossein Babaahmadi Rezaei; Reihaneh Mousavi
Journal:  Nutr Metab (Lond)       Date:  2021-06-06       Impact factor: 4.169

8.  Serum Trace Elements in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Jiechen Yin; Xiang Hong; Jun Ma; Yuanqing Bu; Ran Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-17       Impact factor: 5.555

9.  Associations of Serum Magnesium With Insulin Resistance and Testosterone in Women With Polycystic Ovary Syndrome.

Authors:  Xi Luo; Wang-Yu Cai; Hong-Li Ma; Jing Cong; Hui Chang; Jing-Shu Gao; Wen-Juan Shen; Yu Wang; Xin-Ming Yang; Xiao-Ke Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-23       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.